Co-Authors
This is a "connection" page, showing publications co-authored by Gregory Karczmar and Milica Medved.
Connection Strength
8.667
-
Characterization of Effects of Compressed Sensing on High Spectral and Spatial Resolution (HiSS) MRI with Comparison to SENSE. Tomography. 2023 03 19; 9(2):693-705.
Score: 0.885
-
High spectral and spatial resolution MRI of prostate cancer: a pilot study. Magn Reson Med. 2021 09; 86(3):1505-1513.
Score: 0.778
-
Fast bilateral breast coverage with high spectral and spatial resolution (HiSS) MRI at 3T. J Magn Reson Imaging. 2017 11; 46(5):1341-1348.
Score: 0.582
-
Non-contrast enhanced MRI for evaluation of breast lesions: comparison of non-contrast enhanced high spectral and spatial resolution (HiSS) images versus contrast enhanced fat-suppressed images. Acad Radiol. 2011 Dec; 18(12):1467-74.
Score: 0.400
-
Echo-planar spectroscopic imaging (EPSI) of the water resonance structure in human breast using sensitivity encoding (SENSE). Magn Reson Med. 2010 Jun; 63(6):1557-63.
Score: 0.365
-
Fourier component imaging of water resonance in the human breast provides markers for malignancy. Phys Med Biol. 2009 Oct 07; 54(19):5767-79.
Score: 0.347
-
Clinical implementation of a multislice high spectral and spatial resolution-based MRI sequence to achieve unilateral full-breast coverage. Magn Reson Imaging. 2010 Jan; 28(1):16-21.
Score: 0.343
-
High spectral and spatial resolution MRI of breast lesions: preliminary clinical experience. AJR Am J Roentgenol. 2006 Jan; 186(1):30-7.
Score: 0.268
-
Introduction to matrix-based method for analyzing hybrid multidimensional prostate MRI data. J Appl Clin Med Phys. 2024 Nov 20; e14544.
Score: 0.248
-
Fourier components of inhomogeneously broadened water resonances in breast: a new source of MRI contrast. Magn Reson Med. 2004 Jul; 52(1):193-6.
Score: 0.242
-
Self-supervised multicontrast super-resolution for diffusion-weighted prostate MRI. Magn Reson Med. 2024 Jul; 92(1):319-331.
Score: 0.235
-
The effect of varying spectral resolution on the quality of high spectral and spatial resolution magnetic resonance images of the breast. J Magn Reson Imaging. 2003 Oct; 18(4):442-8.
Score: 0.230
-
Standardization of Breast Dynamic Contrast-enhanced MRI Signal with Application to the Assessment of Background Parenchymal Enhancement Rate. Curr Med Imaging. 2023 Mar 06.
Score: 0.221
-
Directional and inter-acquisition variability in diffusion-weighted imaging and editing for restricted diffusion. Magn Reson Med. 2022 11; 88(5):2298-2310.
Score: 0.211
-
Differences Between Ipsilateral and Contralateral Early Parenchymal Enhancement Kinetics Predict Response of Breast Cancer to Neoadjuvant Therapy. Acad Radiol. 2022 10; 29(10):1469-1479.
Score: 0.207
-
Signal intensity form of the Tofts model for quantitative analysis of prostate dynamic contrast enhanced MRI data. Phys Med Biol. 2021 01 22; 66(2):025002.
Score: 0.191
-
A compact solution for estimation of physiological parameters from ultrafast prostate dynamic contrast enhanced MRI. Phys Med Biol. 2019 08 07; 64(15):155012.
Score: 0.172
-
Low-dose imaging technique (LITE) MRI: initial experience in breast imaging. Br J Radiol. 2019 Nov; 92(1103):20190302.
Score: 0.171
-
Use of Indicator Dilution Principle to Evaluate Accuracy of Arterial Input Function Measured With Low-Dose Ultrafast Prostate Dynamic Contrast-Enhanced MRI. Tomography. 2019 06; 5(2):260-265.
Score: 0.170
-
Comparison of arterial input functions measured from ultra-fast dynamic contrast enhanced MRI and dynamic contrast enhanced computed tomography in prostate cancer patients. Phys Med Biol. 2018 01 30; 63(3):03NT01.
Score: 0.155
-
Ultrafast Bilateral DCE-MRI of the Breast with Conventional Fourier Sampling: Preliminary Evaluation of Semi-quantitative Analysis. Acad Radiol. 2016 09; 23(9):1137-44.
Score: 0.138
-
Arterial input functions (AIFs) measured directly from arteries with low and standard doses of contrast agent, and AIFs derived from reference tissues. Magn Reson Imaging. 2016 Feb; 34(2):197-203.
Score: 0.133
-
B1 and T1 mapping of the breast with a reference tissue method. Magn Reson Med. 2016 Apr; 75(4):1565-73.
Score: 0.129
-
Comparison of dynamic contrast-enhanced MRI parameters of breast lesions at 1.5 and 3.0?T: a pilot study. Br J Radiol. 2015 May; 88(1049):20150021.
Score: 0.127
-
High-resolution diffusion-weighted imaging of the prostate. AJR Am J Roentgenol. 2014 Jul; 203(1):85-90.
Score: 0.121
-
Hybrid multidimensional T(2) and diffusion-weighted MRI for prostate cancer detection. J Magn Reson Imaging. 2014 Apr; 39(4):781-8.
Score: 0.114
-
Classification of breast lesions pre-contrast injection using water resonance lineshape analysis. NMR Biomed. 2013 May; 26(5):569-77.
Score: 0.108
-
Do we really need contrast agents? Eur J Radiol. 2012 Sep; 81 Suppl 1:S99-100.
Score: 0.107
-
Sensitivity to tumor microvasculature without contrast agents in high spectral and spatial resolution MR images. Magn Reson Med. 2009 Feb; 61(2):291-8.
Score: 0.083
-
Quantitative analysis of water proton spectral lineshape: a novel source of contrast in MRI. Phys Med Biol. 2008 Sep 07; 53(17):4509-22.
Score: 0.080
-
Fat suppression with spectrally selective inversion vs. high spectral and spatial resolution MRI of breast lesions: qualitative and quantitative comparisons. J Magn Reson Imaging. 2006 Dec; 24(6):1311-5.
Score: 0.072
-
Quantitative Multi-Parametric MRI of the Prostate Reveals Racial Differences. Cancers (Basel). 2024 Oct 16; 16(20).
Score: 0.062
-
Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging. 2004 Jul; 20(1):122-8.
Score: 0.060
-
New model for analysis of dynamic contrast-enhanced MRI data distinguishes metastatic from nonmetastatic transplanted rodent prostate tumors. Magn Reson Med. 2004 Mar; 51(3):487-94.
Score: 0.059
-
Prostate Cancers Invisible on Multiparametric MRI: Pathologic Features in Correlation with Whole-Mount Prostatectomy. Cancers (Basel). 2023 Dec 13; 15(24).
Score: 0.058
-
Safely reducing unnecessary benign breast biopsies by applying non-mass and DWI directional variance filters to ADC thresholding. BMC Med Imaging. 2022 09 29; 22(1):171.
Score: 0.054
-
Breast MR imaging with high spectral and spatial resolutions: preliminary experience. Radiology. 2002 Aug; 224(2):577-85.
Score: 0.053
-
Spectrally inhomogeneous effects of contrast agents in breast lesion detected by high spectral and spatial resolution MRI. Acad Radiol. 2002 Aug; 9 Suppl 2:S352-4.
Score: 0.053
-
Physically implausible signals as a quantitative quality assessment metric in prostate diffusion-weighted MR imaging. Abdom Radiol (NY). 2022 07; 47(7):2500-2508.
Score: 0.052
-
Robustness of radiomic features of benign breast lesions and hormone receptor positive/HER2-negative cancers across DCE-MR magnet strengths. Magn Reson Imaging. 2021 10; 82:111-121.
Score: 0.049
-
T2*-weighted MRI as a non-contrast-enhanced method for assessment of focal laser ablation zone extent in prostate cancer thermotherapy. Eur Radiol. 2021 Jan; 31(1):325-332.
Score: 0.046
-
Discrimination of benign from malignant breast lesions in dense breasts with model-based analysis of regions-of-interest using directional diffusion-weighted images. BMC Med Imaging. 2020 06 09; 20(1):61.
Score: 0.046
-
Spectral characterization of tissues in high spectral and spatial resolution MR images: Implications for a classification-based synthetic CT algorithm. Med Phys. 2017 May; 44(5):1865-1875.
Score: 0.037
-
Breast density estimation from high spectral and spatial resolution MRI. J Med Imaging (Bellingham). 2016 Oct; 3(4):044507.
Score: 0.036
-
Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer. 2017 04; 15(2):207-212.
Score: 0.035
-
Pilot Study of the Use of Hybrid Multidimensional T2-Weighted Imaging-DWI for the Diagnosis of Prostate Cancer and Evaluation of Gleason Score. AJR Am J Roentgenol. 2016 Sep; 207(3):592-8.
Score: 0.035
-
Short-term reproducibility of apparent diffusion coefficient estimated from diffusion-weighted MRI of the prostate. Abdom Imaging. 2015 Oct; 40(7):2523-8.
Score: 0.033
-
Preliminary assessment of dispersion versus absorption analysis of high spectral and spatial resolution magnetic resonance images in the diagnosis of breast cancer. J Med Imaging (Bellingham). 2015 Apr; 2(2):024502.
Score: 0.032
-
Residual analysis of the water resonance signal in breast lesions imaged with high spectral and spatial resolution (HiSS) MRI: a pilot study. Med Phys. 2014 Jan; 41(1):012303.
Score: 0.029
-
Prostate volumes derived from MRI and volume-adjusted serum prostate-specific antigen: correlation with Gleason score of prostate cancer. AJR Am J Roentgenol. 2013 Nov; 201(5):1041-8.
Score: 0.029
-
Potential of computer-aided diagnosis of high spectral and spatial resolution (HiSS) MRI in the classification of breast lesions. J Magn Reson Imaging. 2014 Jan; 39(1):59-67.
Score: 0.029
-
Characterizing early contrast uptake of ductal carcinoma in situ with high temporal resolution dynamic contrast-enhanced MRI of the breast: a pilot study. Phys Med Biol. 2010 Oct 07; 55(19):N473-85.
Score: 0.023
-
Reproducibility assessment of a multiple reference tissue method for quantitative dynamic contrast enhanced-MRI analysis. Magn Reson Med. 2009 Apr; 61(4):851-9.
Score: 0.021
-
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8.
Score: 0.020
-
Multiple reference tissue method for contrast agent arterial input function estimation. Magn Reson Med. 2007 Dec; 58(6):1266-75.
Score: 0.019
-
Diagnosis of suspicious breast lesions using an empirical mathematical model for dynamic contrast-enhanced MRI. Magn Reson Imaging. 2007 Jun; 25(5):593-603.
Score: 0.018
-
Multi-slice DCE-MRI data using P760 distinguishes between metastatic and non-metastatic rodent prostate tumors. MAGMA. 2006 Feb; 19(1):15-21.
Score: 0.017
-
Estimating the arterial input function using two reference tissues in dynamic contrast-enhanced MRI studies: fundamental concepts and simulations. Magn Reson Med. 2004 Nov; 52(5):1110-7.
Score: 0.015
-
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4048-54.
Score: 0.015